San Francisco Investment Firm Buys Two Buildings for $60 Million, Takes Stake in Four Others
By Lou Hirsh CoStar News October 3, 2022 | 5:43 P.M.
A San Francisco-based investment firm acquired a two-building life science portfolio in San Diego for approximately $60 million and took a majority stake in four other buildings, underscoring strong demand in one of the nation’s largest biotech cluster regions.
GI Partners purchased the properties totaling approximately 81,000 square feet, at 7330 and 7360 Carroll Road in the Mira Mesa neighborhood from Alexandria Real Estate Equities of Pasadena, California, according to the buyer and public data.
The buildings were constructed in 1982 and 1983 and renovated in 2007, with current tenants including biotech firm Catalent and DEC Engineers. CoStar and public data show Alexandria paid approximately $23.3 million for the 7330 building in July 2010 and $6.3 million for the 7360 building in August 2021.
In a separate deal, GI Partners said it also acquired a 70% interest in a four-building Sorrento Mesa portfolio owned by Alexandria at 9965-9995 Summers Ridge Road, totaling approximately 316,000 square feet. The price was not disclosed, but Alexandria paid approximately $148.6 million for the portfolio in January 2018, according to public data.
In a statement, GI Partners Managing Director John Sheputis said fundamentals in the San Diego neighborhoods remain robust, “with steady demand and tightening supply as tenants seek access to the highly skilled San Diego workforce and its concentration of intellectual capital.”
Mira Mesa and the adjacent Sorrento Mesa neighborhood of central San Diego have long been hubs for technology and life science firms, and Sorrento Mesa in particular has seen a wave of property purchases and redevelopments geared to the biotech industry over the past three years.
A second-quarter report from brokerage CBRE noted that San Diego’s biotech vacancy rate was 3.6%, well below the national biotech vacancy rate of 5.2%. The brokerage said space being sought by San Diego biotech tenants at the end of the quarter totaled approximately 1.5 million square feet, with 4.7 million square feet of new and converted space under construction. Nearly a quarter of space under construction was preleased.
A September national life science report from brokerage JLL reaffirmed San Diego’s status as the third-largest hub for biotech real estate supply and demand after Boston and San Francisco, a spot it has held for several years. While falling below year-earlier levels, venture funding for the biotech industry remained historically high in the second quarter, totaling about $8 billion for the three top cluster markets, including about $1 billion in San Diego.
All content provided on this blog is for informational purposes only. The owner of this blog makes no representations as to the accuracy or completeness of any information on this site or found by following any link on this site. The owner of will not be liable for any errors or omissions in this information nor for the availability of this information. The owner will not be liable for any losses, injuries, or damages from the display or use of this information. Keywords: San Diego Commercial Real Estate For Sale, Commercial Property In San Diego, Commercial Real Estate In San Diego, San Diego Investment Real Estate, Commercial Property Management In San Diego, San Diego Commercial Property Management, Commercial Property Management San Diego, Managed Commercial Property San Diego, Commercial Property For Sale San Diego, San Diego Commercial Real Estate Leasing, Top Real Estate Agents in San Diego, Commercial Property in San Diego, Property Management Company San Diego, Real Estate Agent in San Diego, San Diego Commercial Real Estate Real Estate Agent Contact Us Brokerage, Property Management Commercial Real Estate Agency in San Diego San Diego Commercial Property Management